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Influence of Sex on Long-Term Outcomes
After Percutaneous Coronary Intervention
With the Paclitaxel-Eluting Coronary Stent
Results of the “TAXUS Woman” Analysis
Ghada W. Mikhail, MD,* Robert T. Gerber, MD, PHD,* David A. Cox, MD,†
Stephen G. Ellis, MD,‡ John M. Lasala, MD,§ John A. Ormiston, MBCHB,储
Gregg W. Stone, MD,¶ Mark A. Turco, MD,# Anita A. Joshi, PHD,**
Donald S. Baim, MD,** Antonio Colombo, MD††
London, United Kingdom; Allentown, Pennsylvania; Cleveland, Ohio; St. Louis, Missouri;
Auckland, New Zealand; New York, New York; Takoma Park, Maryland; Natick, Massachusetts;
and Milan, Italy

Objectives We conducted the “TAXUS Woman” analysis to assess the inﬂuence of sex on long-term
outcomes after percutaneous coronary intervention using paclitaxel-eluting stents (PES) in a broad
spectrum of patients.
Background Previous studies indicate that the sex gap suggesting worse outcomes in women has
narrowed. However, limited data are available on long-term sex-based outcomes with drug-eluting
stents despite their extensive use in current practice.
Methods We analyzed 2,271 PES-treated patients (women ⫽ 665), from 5 randomized trials and 7,492
PES-treated patients (women ⫽ 2,449) from 2 “real-world” registries. The trial and registry datasets were
stratiﬁed by sex to compare long-term outcomes. Additionally, the outcomes in PES-treated women were
compared with bare-metal stent–treated women (n ⫽ 395) in the randomized trials.
Results In the randomized trials, PES-treated women had a lower target lesion revascularization
(TLR) rate (11.5% vs. 22.6%, p ⬍ 0.001) than bare-metal stent–treated women, with no signiﬁcant
sex-based differences in death, myocardial infarction, stent thrombosis, or TLR through 5 years. In
both the trials and the registries, although women had more adverse baseline characteristics including advanced age, hypertension, and diabetes, they had similar outcomes to men. In expanded-use
patients, however, women showed signiﬁcantly higher rates of death and TLR, although only the
higher TLR rate was conﬁrmed by multivariate analysis.
Conclusions This study of nearly 10,000 patients including more than 3,000 women demonstrates that
despite their higher-risk proﬁle, women have comparable beneﬁts to men from percutaneous coronary
intervention with PES except for a slightly higher revascularization rate in the high-risk cohort. (J Am
Coll Cardiol Intv 2010;3:1250 –9) © 2010 by the American College of Cardiology Foundation

From the *Department of Cardiovascular Medicine, Imperial College Healthcare National Health Service Trust, London, United
Kingdom; †Lehigh Valley Heart Specialists, Allentown, Pennsylvania; ‡Cleveland Clinic, Department of Cardiology, Cleveland, Ohio;
§Washington University School of Medicine, Cardiovascular Division, St. Louis, Missouri; 储Mercy Angiography Unit, Mercy Hospital,
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Downloaded for library services (libraryservices@lvhn.org) at Lehigh Valley Health Network from ClinicalKey.com by Elsevier on
August 26, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 3, NO. 12, 2010
DECEMBER 2010:1250 –9

Coronary artery disease is the leading cause of death for
both men and women in the U.S. and other developed
countries. For more than 2 decades, more women than
men have died of this disease (1). However, women
continue to be under-represented in prospective clinical
trials evaluating coronary revascularization strategies.
Furthermore, compared with men, women tend to have
more comorbid conditions at baseline and potentially
complex coronary anatomy, challenging the validity of
making treatment decisions for women based on data
derived from predominantly male populations. A better
understanding of sex-specific outcomes would potentially
allow individualized revascularization strategies to be
developed for the large and growing population of
women with coronary artery disease.
See page 1260

Previous sex-based studies in patients undergoing percutaneous coronary intervention (PCI) and coronary artery
bypass graft have reported higher in-hospital mortality and
increased risk for adverse outcomes in women than in men
(2– 4). A recent report indicates that, compared with men,
women continue to be at an increased risk of operative
mortality after isolated coronary artery bypass graft, although subsequent studies in patients undergoing PCI with
bare-metal stents (BMS) indicate that the sex gap in
outcomes has narrowed (5–7). In patients undergoing PCI,
the sex gap has narrowed further with the introduction of
drug-eluting stents (DES), where the angiographic and
clinical benefits were found to be independent of sex in
randomized trial cohorts with simple de novo lesions (8,9).
However, the influence of sex on long-term DES outcomes
has not been fully elucidated, and it is not clear if the pattern
of equality holds true outside the realm of low-risk patient
populations. Therefore, we compared sex-based outcomes
in patients receiving paclitaxel-eluting stents (PES) in both
the randomized trials and the “real-world” registries.
Methods
Study description. Data from the TAXUS pivotal trials and
the ATLAS trial were pooled. The TAXUS I, II SR, IV,
and V trials (10 –13) were prospective, multicenter, randomized, double-blind, controlled trials where increasingly complex patients with a single de novo lesion in a native
coronary artery were randomized to receive either a
honoraria from Boston Scientific and Cordis/Johnson & Johnson. Dr. Ormiston has
received research grants and support from Boston Scientific, Johnson & Johnson,
Abbott Vascular, and Elixir Medical as well as honoraria from Boston Scientific and
Abbott Vascular and is an advisory board member for Boston Scientific, Abbott
Vascular, and Devax. Dr. Stone has received research grants from Boston Scientific
and Abbott Vascular. Dr. Turco has received research support and consulting fees
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paclitaxel-eluting Taxus slow-release (commercialized)
stent or an otherwise identical BMS (Boston Scientific
Corporation, Natick, Massachusetts). The TAXUS III trial
evaluating the feasibility and safety of PES for the treatment
of in-stent restenosis and the TAXUS VI trial using the
investigational moderate-release PES were not included in
this analysis (14,15). Follow-up was available through 5
years for the TAXUS I, II, IV, and V trials. The ATLAS
trial (16) is a prospective single-arm trial of the next
generation Taxus Liberté stent (Boston Scientific Corporation) with follow-up available through 4 years.
Data from the ARRIVE (TAXUS Peri-Approved
Registry: A Multicenter Safety Surveillance) 1 and 2
registries (17) were pooled and analyzed separately from
the trial data. The ARRIVE registries are 2-phase
post-market registries undertaken to study Taxus Express2 stent system usage in routine clinical practice
through 2 years.
The pooled analysis design for the randomized trials and
registries is illustrated in Figure 1.
End points and deﬁnitions. The
Abbreviations
following end points were exand Acronyms
amined to assess the influence
BMS ⴝ bare-metal stent(s)
of sex on long-term safety and
DES ⴝ drug-eluting stent(s)
effectiveness of PES: death,
MI ⴝ myocardial infarction
myocardial infarction (MI),
stent thrombosis, and target lePCI ⴝ percutaneous
coronary intervention
sion revascularization (TLR).
PES ⴝ paclitaxel-eluting
Death was defined as all-cause
stent(s)
mortality. Myocardial infarcRVD ⴝ reference vessel
tion was defined as either the
diameter
development of pathological Q
TLR ⴝ target lesion
waves lasting at least 0.04 s in
revascularization
at least 2 contiguous leads with
an elevated creatine kinasemyocardial band fraction level or, in the absence of Q
waves, an elevation of creatine phosphokinase levels to
greater than twice the upper limit of normal with an
elevated creatine kinase-myocardial band level. Stent
thrombosis data, adjudicated by the Academic Research
Consortium “definite or probable” definition, were used
in the present analysis (18). Target lesion revascularization was defined as repeat revascularization by either PCI
or coronary artery bypass graft for ischemia with angiographic restenosis of at least 50% of the luminal diameter
anywhere within the stent or the 5-mm borders proximal
or distal to the stent. Data from the original databases as
from and is a Speakers’ Bureau member for Abbott, Boston Scientific, and Medtronic.
Dr. Joshi is a full-time employee of Boston Scientific. Dr. Baim was a full-time
employee and a stockholder of Boston Scientific. Drs. Gerber and Colombo have
reported that they have no relationships to disclose. Dr. Baim is deceased.
Manuscript received April 30, 2010; revised manuscript received July 16, 2010,
accepted August 6, 2010.
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Figure 1. TAXUS Woman Analysis Design
Patients from 5 randomized trials and 2 “real-world” registries were pooled separately to compare sex-based outcomes.

adjudicated by an independent clinical events committee
for each individual study were used in the present
analysis.
Statistical methods. All statistical analyses were performed by
biostatisticians at Boston Scientific Corporation. Potential bias
was minimized by performing the analysis according to the
intent-to-treat principle by including all patients randomized
in the pooled trials and all patients receiving the Taxus stent in
the pooled registries.
For continuous variables, comparison between the
groups was performed with Student t test. Categorical
variables were compared by the chi-square test. Time-toevent data were calculated and displayed as Kaplan-Meier
estimates with comparison between groups by the logrank test. Statistical significance was set at p ⬍ 0.05.
Annualized s were calculated for every year after the
index procedure using the person-year method. The
approximate Poisson method (19) was used to calculate
the 95% confidence intervals (CIs). Hazard rate differences between groups were calculated using the log-rank
test.
Predictors of clinical outcomes were assessed with
stepwise Cox proportional hazards regression with significance set at 0.05, with the exception of sex, which was
forced into the model. Variables included in the model
for the randomized trials were age, congestive heart
failure, diabetes requiring medication, previous coronary
artery bypass graft, percentage diameter stenosis, in-stent
acute gain, hyperlipidemia, calcification, reference vessel

diameter (RVD), previous MI, minimum lumen diameter, unstable angina, left anterior descending artery versus
non–left anterior descending location, lesion location,
hypertension, smoking, treatment group (Taxus Express
vs. Taxus Liberté), total occlusion, sex, and lesion length.
For the registries, the variables included age, congestive
heart failure, diabetes requiring medication, left main
stenting, prior MI, diabetes requiring insulin, cardiogenic
shock, graft stenting, hypertension, lesion length ⬎28
mm, sex, hyperlipidemia, multiple planned stents, instent restenosis, lesion length, total occlusion, left anterior descending location, RVD, smoking, bifurcation,
multiple lesions treated, RVD ⱕ2.5 mm, percentage
diameter stenosis, and baseline acute MI.
Results
Randomized trials. A total of 2,797 patients were enrolled

in the TAXUS trials; 1,400 were randomized to PES and
1,397 to BMS. The 1,400 PES-treated patients were
pooled with 871 PES-treated patients from the ATLAS
trial (Fig. 1). Of the 2,271 pooled patients, 665 (29.3%)
were women and 1,606 were men.
BASELINE CHARACTERISTICS. As shown in Table 1, women
were significantly older than men, with lower body weight,
more unstable angina, congestive heart failure, medically
treated diabetes, hypertension, prior history of coronary artery
disease, and peripheral vascular disease. They also had slightly
smaller RVD than men did (2.63 ⫾ 0.46 mm vs. 2.79 ⫾ 0.52
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Table 1. Baseline Clinical and Lesion Characteristics for Patients Receiving PES in the Randomized Trials
Variable

Women (n ⴝ 665)
64.9 ⫾ 11.1 (665)

Age, yrs
Weight, lbs

171.3 ⫾ 37.1 (397)

Men (n ⴝ 1,606)
61.4 ⫾ 10.7 (1,606)
200.8 ⫾ 38.4 (970)

p Value
⬍0.001
⬍0.001

Cardiac history
Stable angina

55.1% (365/663)

57.8% (929/1,606)

0.22

Unstable angina

37.4% (248/663)

31.5% (496/1,577)

0.006

Silent ischemia

10.1% (67/665)

12.5% (201/1,602)

0.10

7.7% (51/664)

3.9% (63/1,605)

⬍0.001

Previous myocardial infarction

25.8% (171/663)

31.8% (501/1,577)

0.005

Previous percutaneous coronary intervention

28.0% (174/622)

33.8% (500/1,481)

0.01

5.9% (39/663)

9.3% (146/1,577)

0.008

Current smoking

20.8% (138/665)

23.5% (378/1,606)

0.15

Diabetes, medically treated

33.5% (223/665)

21.9% (352/1,606)

⬍0.001
⬍0.001

Congestive heart failure

Previous coronary artery bypass graft
Cardiac risk factors

Hypertension

78.0% (519/665)

69.5% (1,116/1,606)

Hyperlipidemia

71.7% (477/665)

72.8% (1,166/1,602)

History of coronary artery disease

62.0% (372/600)

52.6% (762/1,450)

⬍0.001

10.2% (63/615)

0.61

Comorbid conditions
Peripheral vascular disease

7.6% (112/1,475)

0.046

Previous transient ischemic attack

3.7% (7/187)

2.9% (14/475)

0.60

Previous cerebrovascular accident

6.0% (27/453)

3.8% (41/1,080)

0.06

Renal disease

5.1% (23/453)

3.9% (42/1,080)

0.29

Lesion characteristics (by QCA)
Reference vessel diameter, mm

2.63 ⫾ 0.46 (659)

2.79 ⫾ 0.52 (1,597)

⬍0.001

Minimum lumen diameter, mm

0.87 ⫾ 0.35 (658)

0.89 ⫾ 0.35 (1,569)

0.24

Diameter stenosis, %

67.09 ⫾ 11.54 (658)

67.98 ⫾ 11.14 (1,569)

0.09

Lesion length, mm

14.65 ⫾ 7.31 (659)

14.72 ⫾ 7.31 (1,592)

0.84

Left anterior descending vessel location

39.0% (259/664)

41.2% (661/1,603)

0.33

Bend ⬎45°

23.8% (148/622)

22.2% (328/1,476)

0.43

Tortuosity

11.9% (74/622)

10.5% (155/1,475)

0.35

Modiﬁed ACC/AHA lesion type
A

8.0% (50/622)

7.1% (105/1,478)

0.45

B1

22.5% (140/622)

24.4% (361/1,478)

0.35

B2

41.6% (259/622)

38.6% (571/1,478)

0.20

C

27.8% (173/622)

29.8% (441/1,478)

0.35

B2/C

69.5% (432/622)

68.5% (1,012/1,478)

0.66

Values are mean ⫾ SD (n) or % (count/sample size). The p values for continuous variables were calculated by Student t test and for categorical
variables were calculated by the chi-square test.
ACC ⫽ American College of Cardiology; AHA ⫽ American Heart Association; PES ⫽ paclitaxel-eluting stent(s); QCA ⫽ quantitative coronary
angiography.

mm, p ⬍ 0.001). In contrast, men were more likely to have had
a previous MI, PCI, and coronary artery bypass graft.
SAFETY AND EFFICACY END POINTS. In the randomized
trials, PES-treated women had significantly lower TLR
rate than BMS-treated women did, with no significant
differences in the rates of death, MI, and stent thrombosis between PES and BMS through 5-year follow-up
(Fig. 2). Comparison of PES-treated women with PEStreated men (Table 2) showed no significant sex differences in all-cause death, MI, and TLR either at 1-year or
between 1 and 5 years. However, women appeared to
suffer less definite/probable stent thrombosis in 0 to 1

year than men did (0.31% vs. 1.27%, p ⫽ 0.04), although this
finding was not sustained during the subsequent years.
The Kaplan-Meier curves in Figure 3 demonstrate the
lack of differences between genders in death, MI, stent
thrombosis, and TLR rates over 5 years. At hospital
discharge, 100% of women and 99.9% of men were receiving dual antiplatelet therapy (p ⫽ 0.52). The antiplatelet
compliance remained similar through follow-up, having
fallen to 36.1% for women and 37.4% for men at 5 years.
MULTIVARIATE PREDICTORS OF 5-YEAR CLINICAL OUTCOMES.

Adjusted for other covariates, sex was not a significant
predictor of any of the adverse outcomes; death (hazard
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Figure 2. Clinical Outcomes for Women in Randomized Trials
Kaplan-Meier estimates of 5-year cumulative rates of death (A), myocardial infarction (B), Academic Research Consortium– deﬁned deﬁnite/probable stent thrombosis (C), and target lesion revascularization (D) for women receiving paclitaxel-eluting stent(s) versus bare-metal stent(s) in the randomized trials. Error bars are
⫾1.5 SE. ARC ⫽ Academic Research Consortium; BMS ⫽ bare-metal stent(s); PES ⫽ paclitaxel-eluting stent(s).

ratio [HR]: 0.83, 95% CI: 0.60 to 1.14), MI (HR: 1.12,
95% CI: 0.80 to 1.58), stent thrombosis (HR: 0.56, 95% CI:
0.27 to 1.16), and TLR (HR: 0.96, 95% CI: 0.72 to 1.26).
Registries. A total of 2,487 and 5,005 patients were
enrolled in the ARRIVE 1 and ARRIVE 2 registries,
Table 2. Annualized Hazard Rates for Patients Receiving PES in the
Randomized Trials
Women
(n ⴝ 665)

Men
(n ⴝ 1,606)

p Value

0–1 yr

1.69%

1.71%

0.97

1–5 yrs

2.20%

1.96%

0.48

0–5 yrs

2.08%

1.90%

0.54

0–1 yr

4.47%

4.06%

0.69

1–5 yrs

1.00%

0.87%

0.62

0–5 yrs

1.86%

1.60%

0.42

0–1 yr

0.31%

1.27%

0.04

1–5 yrs

0.33%

0.35%

0.88

0–5 yrs

0.33%

0.57%

0.13

0–1 yr

7.75%

6.69%

0.39

1–5 yrs

1.60%

1.58%

0.95

0–5 yrs

2.85%

2.67%

0.67

All-cause death

Myocardial infarction

ARC stent thrombosis (deﬁnite/probable)

Target lesion revascularization

ARC ⫽ Academic Research Consortium; PES ⫽ paclitaxel-eluting stent(s).

respectively. Of these 7,492 pooled PES-treated patients,
4,794 (64%) were classified as expanded-use based on
patient and/or lesion characteristics considered outside
the 2,698 simple-use population. The expanded-use cohort included patients with acute MI, lesion length ⬎28
mm, RVD ⬍2.5 mm, multivessel stenting, bifurcation
lesions, in-stent restenosis, vein graft, renal disease, and
chronic total occlusion. Of the 2,698 simple-use patients,
921 (34%) were women and of the 4,794 expanded-use
patients, 1,528 (32%) were women.
BASELINE CHARACTERISTICS. The registry data demonstrated a similar pattern of increased adverse baseline
characteristics for women compared with men (Table 3).
Women were older, more likely to be hypertensive, have
diabetes, previous stroke, and smaller RVD. Men, by
contrast, were more likely to have had a previous MI,
PCI, and coronary artery bypass graft. They were also
more likely to have left main and multivessel disease.
SAFETY AND EFFICACY END POINTS. Simple-use registry patients showed no significant sex differences in death, MI, stent
thrombosis, and TLR through 2 years (Table 4). Also, as in the
randomized trial patients, women tended to have lower stent
thrombosis rates (albeit not statistically significant) than men.
The Kaplan-Meier curves in Figure 4 demonstrate the
absence of sex-based differences in the simple-use patients.
In the expanded-use patients, however, women had significantly higher death and TLR rates than men (Fig. 5).
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Figure 3. Sex-Based Clinical Outcomes in the Randomized Trials
Kaplan-Meier estimates of 5-year cumulative rates of death (A), myocardial infarction (B), Academic Research Consortium (ARC)– deﬁned deﬁnite/probable
stent thrombosis (C), and target lesion revascularization (D) for women versus men for patients receiving paclitaxel-eluting stent(s) in the randomized trials. Error bars are ⫾1.5 SE.

Multivariate predictors of 2-year clinical outcomes. The
higher rates of death and TLR in women in the
expanded-use patients could be confounded by the higher
baseline risk factors in women than in men. This is
supported by multivariate analysis, wherein sex was not
found to be a significant independent predictor of any
adverse outcomes among simple-use patients; death (HR:
0.90, 95% CI: 0.60 to 1.34), MI (HR: 0.94, 95% CI: 0.54
to 1.64), stent thrombosis (HR: 0.62, 95% CI: 0.29 to
1.34), and TLR (HR: 1.39, 95% CI: 0.98 to 1.98). In the
expanded-use patients, sex was not a significant predictor
of death (HR: 1.05, 95% CI: 0.85 to 1.31), MI (HR:
1.18, 95% CI: 0.85 to 1.63), and stent thrombosis (HR:
1.13, 95% CI: 0.80 to 1.61) but remained a significant
predictor of TLR (HR: 1.36, 95% CI: 1.11 to 1.67).
Further, subgroup analysis in the expanded-use
patients indicated that the increase in the TLR rate
in women was generalized across high-risk subgroups,
although no individual subgroup reached statistical significance. The subgroup hazard ratios for TLR (women
vs. men) were as follows: acute MI (HR: 1.48, 95% CI:
0.86 to 2.57), in-stent restenosis (HR: 1.00, 95% CI:
0.59 to 1.72), lesion length ⬎28 mm (HR: 0.94, 95%
CI: 0.61 to 1.44), RVD ⬍2.5 mm (HR: 1.26, 95% CI:
0.56 to 2.86), multivessel stenting (HR: 1.20, 95% CI:
0.85 to 1.69), bifurcation lesion (HR: 1.09, 95% CI: 0.66
to 1.79), chronic total occlusion (HR: 1.38, 95% CI: 0.53
to 3.59).

Discussion
Due to the relative under-representation of women in
PCI trials, and the prior suggestions that women have
worse outcomes than men, more detailed investigations
of the influence of sex on PCI outcomes in current
practice are needed. To our knowledge, the “TAXUS
Woman” analysis, which included more than 3,000
women, is the largest evaluation to date that examines the
influence of sex on long-term performance of a single
DES across low- to high-risk patient/lesion characteristics. This analysis demonstrated that women had significantly more adverse baseline risk factors, yet had comparable safety and efficacy outcomes to men.
The data on 665 women in the randomized trials showed
that PES provided a significant reduction in TLR compared
with BMS through 5 years without an associated increase in
other adverse events. The study extends upon the previous
studies (20,21). It is important to note that because of the
blinded nature of these studies, the use of dual antiplatelet
therapy over time was the same in both the PES and BMS
arms.
In the randomized trials and in the simple-use registry
patients, there were no significant sex-based differences in
long-term safety or efficacy outcomes. In the expanded-use
registry patients, however, univariate analysis showed that
women had significantly higher 1- and 2-year death rates,
which was also observed as a trend in a recent study (21).
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Table 3. Baseline Clinical and Lesion Characteristics for Patients Receiving PES in the Registries
Simple-Use
Variable
Age, yrs

Expanded-Use

Women (n ⴝ 921)

Men (n ⴝ 1,777)

p Value

Women (n ⴝ 1,528)

Men (n ⴝ 3,266)

p Value

65.9 ⫾ 11.5 (921)

61.5 ⫾ 11.2 (1,777)

⬍0.001

67.7 ⫾ 11.8 (1,528)

63.7 ⫾ 11.6 (3,266)

⬍0.001

Cardiac history
Congestive heart failure

6.0% (55/921)

4.4% (79/1,777)

0.08

8.8% (135/1,528)

7.4% (242/3,266)

0.09

Previous myocardial infarction

23.6% (217/921)

28.6% (508/1,777)

0.005

37.7% (576/1,528)

43.5% (1,421/3,266)

⬍0.001

Previous percutaneous coronary
intervention

34.1% (310/910)

35.2% (620/1,759)

0.54

34.1% (513/1,504)

39.6% (1,282/3,235)

⬍0.001

9.5% (87/919)

12.4% (220/1,772)

0.023

18.2% (277/1,520)

28.2% (918/3,260)

⬍0.001

Current smoking

21.3% (196/921)

25.7% (456/1,777)

0.012

20.2% (309/1,528)

24.6% (803/3,266)

⬍0.001

Diabetes, medically treated

28.9% (266/921)

25.0% (444/1,777)

0.029

33.3% (509/1,528)

27.3% (893/3,266)

⬍0.001

Hypertension

80.0% (737/921)

73.0% (1,297/1,777)

⬍0.001

82.2% (1,256/1,528)

73.5% (2,401/3,266)

⬍0.001

Hypercholesteromia

72.5% (668/921)

75.4% (1,339/1,777)

0.11

77.0% (1,176/1,528)

76.4% (2,494/3,266)

0.65
⬍0.001

Previous coronary artery bypass graft
Cardiac risk factors

Comorbid conditions
Previous stroke

5.9% (54/921)

4.6% (81/1,777)

0.14

9.4% (143/1,528)

5.8% (189/3,266)

Renal disease

0.0% (0/921)

0.0% (0/1,777)

Undef

4.4% (67/1,528)

3.8% (124/3,266)

0.33

25.0% (230/921)

28.3% (503/1,777)

0.07

38.0% (581/1,528)

44.4% (1,451/3,266)

⬍0.001

0.0% (0/921)

0.0% (0/1,777)

Undef

6.3% (97/1,528)

8.0% (262/3,266)

0.04

Multivessel disease
Left main disease
Lesion characteristics
Reference vessel diameter (mm)

2.92 ⫾ 0.36 (920)

2.97 ⫾ 0.37 (1,777)

2.87 ⫾ 0.45 (1,528)

2.97 ⫾ 0.48 (3,266)

⬍0.001

Left anterior descending vessel location

43.2% (398/921)

38.9% (691/1,777)

⬍0.001
0.030

47.1% (720/1,528)

40.5% (1,323/3,266)

⬍0.001

A

27.1% (250/921)

23.0% (409/1,777)

0.018

14.4% (220/1,528)

13.5% (441/3,266)

0.40

B1

45.8% (422/921)

47.2% (839/1,777)

0.49

38.5% (588/1,528)

38.2% (1,246/3,266)

0.83

B2

24.8% (228/921)

26.2% (466/1,777)

0.41

41.1% (628/1,528)

41.5% (1,357/3,266)

0.77

C

7.7% (71/921)

8.9% (158/1,777)

0.30

27.8% (425/1,528)

28.9% (945/3,266)

0.42

32.0% (295/921)

34.5% (613/1,777)

0.20

64.7% (988/1,528)

66.2% (2,161/3,266)

0.31

Modiﬁed ACC/AHA lesion type

B2/C

Values are mean ⫾ SD (n) or % (count/sample size). The p values for continuous variables were calculated by Student t test and for categorical variables were calculated by the chi-square test.
Undef ⫽ undefined; other abbreviations as in Table 1.

Multivariate analysis, however, showed that this observed
increase in mortality in women in the expanded-use patients
was attributable to their higher baseline comorbidities (including age and diabetes), making sex per se a marker of a more
severe clinical profile rather than a variable that directly affects
the outcome. This observation is in alignment with previous
studies that reported no differences in short- or long-term
differences in mortality between men and women after adjustment for baseline covariates in the modern era of PCI with
DES in patients with de novo lesions (22,23).
A more interesting finding of this study is the increase in
TLR for women in the expanded-use registry population. Our
finding is supported by a previous report wherein female sex
has been reported as an independent predictor of restenosis
following sirolimus-eluting stent implantation in high-risk
patients (24). Also a recent pooled sex-based analysis comparing the everolimus-eluting stent and PES demonstrated that
irrespective of the stent type, a higher 2-year TLR rate was
observed in women than in men (7.3 vs. 4.2, p ⫽ 0.03) (25).
Sex differences in intravascular ultrasound measures of neointimal hyperplasia have been reported previously (26). The fact

that increases in the rate of repeat revascularization were
limited to the expanded-use registry population in the PES
registries suggests that this slightly greater level of neointimal
hyperplasia may only become clinically relevant in more complex lesions. Unlike the increase in death rate, the increase in
TLR for women persisted after multivariate adjustment, suggesting a fundamental biologic difference or perhaps the effect
of other unmeasured confounders.
Some concerns have been raised about the potential for
increased very late (after 1 year) rates of stent thrombosis with
DES versus BMS (27). It has been postulated that DES might
be more vulnerable to this complication due to potential
suppression of neointimal hyperplasia and the altered vascular
responses by the antiproliferative effects responsible for the
desired reduction in restenosis. Although this event occurs
with low frequency, it is associated with significant morbidity
and mortality. In that context, it is of interest that a moderately
significant reduction in stent thrombosis at 12 months in favor
of women was observed in both the trial and simple-use
registry patients. However, this initial benefit in terms of stent
thrombosis was not sustained to 5 years, nor did it persist after
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Table 4. Annualized s for Patients Receiving PES in the Registries
Simple-Use

Expanded-Use

Women
(n ⴝ 921)

Men
(n ⴝ 1,777)

p Value

Women
(n ⴝ 1,528)

Men
(n ⴝ 3,266)

p Value

0–1 yr

2.47%

2.22%

0.68

5.37%

3.82%

0.02

1–2 yrs

2.19%

1.92%

0.65

4.21%

3.64%

0.39

0–2 yrs

2.34%

2.07%

0.55

4.82%

3.74%

0.02

0–1 yr

1.25%

1.47%

0.65

2.95%

2.51%

0.41

1–2 yrs

0.98%

0.83%

0.72

1.23%

1.53%

0.46

0–2 yrs

1.12%

1.14%

0.96

2.15%

1.99%

0.64

0–1 yr

0.68%

1.06%

0.34

2.51%

2.21%

0.54

1–2 yrs

0.37%

0.64%

0.39

1.00%

1.31%

0.41

0–2 yrs

0.53%

0.80%

0.29

1.77%

1.74%

0.93

0–1 yr

4.13%

3.14%

0.20

8.06%

5.69%

0.004

1–2 yrs

2.84%

2.46%

0.59

4.15%

3.86%

0.67

0–2 yrs

3.27%

2.60%

0.19

5.82%

4.60%

0.02

All-cause death

Myocardial infarction

ARC stent thrombosis (deﬁnite/probable)

Target lesion revascularization

Abbreviations as in Tables 1, 2, and 3.

multivariate adjustment for other baseline differences. It was
also not explicable by women being more likely to adhere to
dual antiplatelet therapy, given similar rates of medication
compliance over time, for men and women. It is possible

that the lower body weight of women compared with the
body weight of men could lead to higher dosing of clopidogrel (milligrams per kilograms body weight), and thus
more effective antiplatelet effect during the first year, but

Figure 4. Sex-Based Clinical Outcomes in the Registries (Simple-Use)
Kaplan-Meier estimates of 2-year cumulative rates of death (A), myocardial infarction (B), Academic Research Consortium (ARC)– deﬁned deﬁnite/probable stent
thrombosis (C), and target lesion revascularization (D) for women versus men in simple-use patients receiving paclitaxel-eluting stent(s) in the registries. Error
bars are ⫾1.5 SE.
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Figure 5. Sex-Based Clinical Outcomes in the Registries (Expanded-Use)
Kaplan-Meier estimates of 2-year cumulative rates of death (A), myocardial infarction (B), Academic Research Consortium (ARC)– deﬁned deﬁnite/probable stent
thrombosis (C), and target lesion revascularization (D) for women versus men in expanded-use patients receiving paclitaxel-eluting stents in the registries. Error
bars are ⫾1.5 SE.

recent data suggest that sex is a significant predictor of
heightened platelet reactivity despite dual antiplatelet therapy in patients undergoing PCI (28). Hence, we cannot
exclude that this observation of reduced first-year stent
thrombosis in women was the result of a type 2 error,
making further clarification from a larger prospective study
warranted before concluding that there is a real difference in
early stent thrombosis for women.
Study limitations. This study based on a large cohort of
PES-treated women was subjected to careful ascertainment
of follow-up events. However, as a post hoc subset analysis
of prospective trials and registries it still must be considered
as an observational and hypothesis-generating study. In
addition, although the results of this analysis cannot be
applied directly to women with more diffuse disease, acute
MI, or those requiring multivessel intervention, the inclusion of expanded-use conditions in the real-world registries
may provide insight into sex differences when DES are used
in such high-risk patients. Finally, it remains to be determined whether DES other than Taxus would show the
same relative results in women compared with men.

differences in key adverse outcomes such as death, MI,
TLR, or stent thrombosis in the randomized trial and
simple-use registry patients. However, a slightly higher
rate of TLR was observed in women in the overall
expanded-use registry patients, across the subgroups
usually associated with an increased risk of restenosis.
Nonetheless, this large sex-based analysis demonstrates
that PCI with PES is a safe and effective treatment
option for women with coronary artery disease suitable
for revascularization with DES.
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Conclusions
These data indicate that the overall beneficial effects of
PES in reducing revascularization compared with BMS
are generalizable to women. There were no sex-based
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